Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow

Jul 28, 2010

Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow 10.6 KB

BRIDGEWATER, N.J., Jul 28, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended June 30, 2010, on Tuesday, August 3, 2010 at 4:00 pm Eastern Time (ET). The release will be followed by a live conference call, which will begin at 5:00 pm Eastern Time (ET) on Tuesday, August 3, 2010.

All interested parties may access the call by using the following information:

Domestic Dial-In Number:	(877) 561-2748
International Dial-In Number:	(720) 545-0044
Access Code:	Enzon

The call will also be available via live audio webcast at the following site: http://investor.enzon.com/eventdetail.cfm?eventid=84459. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, August, 3, 2010 at approximately 8:00 pm Eastern Time (ET) and end on Tuesday, August 10, 2010 at approximately 11:59pm Eastern Time (ET). It may be accessed using the following information:

Domestic Dial-In Number:	(800) 642-1687
International Dial-In Number:	(706) 645-9291
Conference I.D.:	90977127

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative medicines for patients with cancer. Enzon's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform, Customized Linker technology(TM) and mRNA antagonists using the Locked Nucleic Acid(TM) (LNA) technology. Enzon receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

SOURCE: Enzon Pharmaceuticals, Inc.

Argot Partners
Andrea Rabney, 212-600-1902
andrea@argotpartners.com